IBJNews

Lilly enters collaboration deal with Swiss company

Back to TopCommentsE-mailPrintBookmark and Share

Drugmaker Eli Lilly and Co. has signed a deal with Swiss company Synthes Inc. to co-promote the bone drug Forteo and develop other potential orthopedic treatments. Terms of the deal were not disclosed.

Lilly, based in Indianapolis, said Thursday it will license some early-stage or pre-clinical compounds to Synthes for that company to develop and possibly sell. The companies also will team to study an additional use for Forteo in fracture healing.

Forteo is approved to help build new bone in osteoporosis patients. It generated $216.1 million in sales during the first quarter.

Lilly and Synthes also will co-promote Forteo to U.S. orthopedic surgeons, who treat patients with fractures due to osteoporosis.

Synthes specializes in developing and selling instruments, implants and biomaterials to fix bone and soft tissues. U.S. prosecutors in Philadelphia are seeking prison time for some former Synthes executives who have pleaded guilty to misdemeanors tied to allegations that company representatives pushed a bone-cement product for an unapproved use.

Lilly spokeswoman Tammy Hull noted that the executives are no longer with the company and Lilly was excited about working with Synthes.

Lilly shares rose 49 cents, or 1.3 percent, to $37.76 each in afternoon trading.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT